Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 2/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.37 |
| ▸ | THRB | P10828 | 1/20 | 0.37 |
| ▸ | S1PR5 | Q9H228 | 1/20 | 0.36 |
| ▸ | ANO1 | Q5XXA6 | 1/20 | 0.36 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6482569 | 0.92 | KMT2A (0.40) | KMT2AALDH1A1LMNAMEN1SMN1; SMN2 | |
| SCHEMBL8906824 | 0.90 | KMT2A (0.49) | KMT2AALDH1A1LMNASMN1; SMN2ANO1 | |
| SCHEMBL6475343 | 0.89 | KMT2A (0.42) | KMT2AALDH1A1LMNAMEN1SMN1; SMN2 | |
| SCHEMBL6474740 | 0.88 | KMT2A (0.41) | KMT2AALDH1A1LMNAMEN1SMN1; SMN2 | |
| SCHEMBL6482527 | 0.87 | KMT2A (0.41) | KMT2AALDH1A1LMNAMEN1SMN1; SMN2 | |
| SCHEMBL6481625 | 0.86 | LPAR1 (0.45) | KMT2AALDH1A1LMNASMN1; SMN2THRB | |
| SCHEMBL6475232 | 0.86 | KMT2A (0.40) | KMT2AALDH1A1LMNAMEN1SMN1; SMN2 | |
| SCHEMBL8905521 | 0.85 | ALDH1A1 (0.50) | KMT2AALDH1A1LMNASMN1; SMN2GAA | |
| SCHEMBL6475681 | 0.85 | LPAR1 (0.46) | ALDH1A1LMNASMN1; SMN2THRB | |
| SCHEMBL6485593 | 0.85 | LPAR1 (0.46) | ALDH1A1LMNASMN1; SMN2THRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6939888-B2 | 1-H-3-arylpirrolidine-2,4-dione derivatives | BAYER AKTIENGESELLSCHAFT (DE) | 2005-09-06 | — | — | US | disclosed |
| US-20040019061-A1 | 1-H-3-arylpirrolidine-2,4-dione derivatives | FISCHER REINER (DE) | 2004-01-29 | — | — | US | disclosed |
| US-6472419-B1 | 1-H-3-aryl-pyrrolidine-2, 4-dione derivatives as pest-control agents | BAYER AKTIENGESELLSCHAFT (DE) | 2002-10-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040019061-A1 | 1-H-3-arylpirrolidine-2,4-dione derivatives | PRXL2A, DDT, CYP4B1 | KMT2A 2190/4885ALDH1A1 792/4885LMNA 2427/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.